Table 1.
Clinical effects of high H2 water and patient characteristics at baseline, and 4, 8, and 12 weeks
| |
Patients |
Disease duration |
Urinary 8-OHdG (ng/mg Cr) |
DAS28 |
ACPA (U/ml) |
Medications |
|
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |
|
|
|
|
Baseline |
4w |
8w |
12w |
Baseline |
4w |
8w |
12w |
Baseline |
4w |
8w |
12w |
MTX (mg/w) |
Duration |
Abatacept (mg/4w) |
Duration |
Response |
||
| Patient number | Sex | Age | Y | M | Y | M | Y | M | |||||||||||||||
| 1 |
F |
67 |
3 |
2 |
10.1 |
10.0 |
7.7 |
6.0 |
3.28 |
2.45 |
2.40 |
1.94 |
300 |
204 |
254 |
226 |
6 |
2 |
0 |
500 |
1 |
2 |
good |
| 2 |
F |
69 |
5 |
0 |
18.0 |
16.2 |
12.0 |
11.5 |
2.90 |
2.95 |
2.53 |
2.62 |
<0.6 |
<0.6 |
<0.6 |
<0.6 |
4 |
2 |
1 |
|
|
|
non-response |
| 3 |
F |
76 |
11 |
0 |
11.0 |
8.1 |
7.8 |
7.8 |
4.61 |
3.71 |
3.28 |
3.01 |
52.4 |
47.2 |
58.0 |
56.6 |
6 |
3 |
0 |
|
|
|
good |
| 4 |
F |
51 |
2 |
1 |
11.4 |
11.3 |
9.1 |
9.4 |
3.00 |
2.79 |
2.86 |
2.30 |
<0.6 |
<0.6 |
<0.6 |
<0.6 |
6 |
1 |
6 |
|
|
|
moderate |
| 5 |
F |
41 |
2 |
0 |
10.9 |
9.9 |
11.3 |
10.0 |
4.55 |
3.43 |
3.06 |
3.13 |
6.9 |
6.2 |
9.2 |
14.5 |
none |
good |
|||||
| 6 |
F |
42 |
2 |
2 |
15.3 |
12.6 |
11.6 |
10.8 |
4.63 |
4.03 |
2.44 |
2.57 |
<0.6 |
<0.6 |
<0.6 |
<0.6 |
6 |
1 |
4 |
|
|
|
good |
| 7 |
F |
86 |
5 |
0 |
10.0 |
6.5 |
7.1 |
7.1 |
4.67 |
3.79 |
3.78 |
3.00 |
0.8 |
<0.6 |
<0.6 |
<0.6 |
none |
good |
|||||
| 8 |
F |
40 |
10 |
0 |
nd |
nd |
3.9 |
4.9 |
2.88 |
1.25 |
1.50 |
0.99 |
13.5 |
14.5 |
15.4 |
16.8 |
6 |
2 |
2 |
|
|
|
good |
| 9 |
F |
41 |
2 |
1 |
8.7 |
7.7 |
7.3 |
9.0 |
5.38 |
4.35 |
4.37 |
4.22 |
34.3 |
36.4 |
57.6 |
65.7 |
8 |
1 |
6 |
|
|
|
moderate |
| 10 |
M |
55 |
2 |
3 |
9.3 |
8.3 |
9.7 |
11.5 |
4.62 |
3.44 |
3.28 |
3.06 |
532 |
258 |
299 |
223 |
6 |
1 |
8 |
|
|
|
good |
| 11 |
F |
56 |
2 |
0 |
12.0 |
8.2 |
10.8 |
10.9 |
5.47 |
5.22 |
5.06 |
4.16 |
<0.6 |
<0.6 |
<0.6 |
<0.6 |
|
|
|
500 |
0 |
8 |
good |
| 12 |
M |
40 |
2 |
1 |
5.2 |
4.9 |
4.9 |
6.4 |
1.95 |
1.96 |
1.52 |
1.59 |
<0.6 |
<0.6 |
<0.6 |
<0.6 |
6 |
1 |
4 |
|
|
|
non-response |
| 13 |
F |
64 |
13 |
0 |
nd |
8.1 |
11.2 |
9.0 |
2.72 |
2.14 |
2.32 |
2.21 |
490 |
299 |
266 |
256 |
4 |
7 |
0 |
|
|
|
non-response |
| 14 |
F |
58 |
2 |
0 |
10.7 |
8.4 |
8.5 |
10.5 |
3.21 |
3.03 |
2.93 |
3.04 |
<0.6 |
<0.6 |
<0.6 |
<0.6 |
6 |
1 |
2 |
|
|
|
non-response |
| 15 |
F |
74 |
3 |
0 |
6.5 |
6.8 |
5.7 |
5.3 |
2.91 |
2.52 |
2.30 |
1.30 |
<0.6 |
<0.6 |
<0.6 |
<0.6 |
none |
good |
|||||
| 16 |
F |
69 |
0 |
8 |
7.6 |
6.5 |
8.6 |
5.4 |
4.07 |
2.78 |
2.54 |
0.99 |
2 |
3.7 |
<0.6 |
1.9 |
none |
good |
|||||
| 17 |
M |
42 |
0 |
9 |
7.9 |
5.7 |
6.6 |
7.2 |
3.25 |
2.03 |
2.27 |
1.11 |
<0.6 |
<0.6 |
<0.6 |
<0.6 |
6 |
|
6 |
|
|
|
good |
| 18 |
F |
49 |
0 |
5 |
10.6 |
8.5 |
7.2 |
9.3 |
4.91 |
3.46 |
2.83 |
1.17 |
<0.6 |
<0.6 |
<0.6 |
<0.6 |
none |
good |
|||||
| 19 |
F |
57 |
0 |
10 |
9.5 |
9.4 |
9.2 |
10.7 |
3.38 |
2.87 |
2.50 |
1.82 |
<0.6 |
<0.6 |
<0.6 |
<0.6 |
none |
good |
|||||
| 20 | F | 41 | 0 | 8 | 5.2 | 5.0 | 4.4 | 3.8 | 4.20 | 2.29 | 2.91 | 0.99 | <0.6 | <0.6 | <0.6 | <0.6 | none | good | |||||
And, no urine sample; DAS28, disease activity score in 28 joints; ACPA, antibodies against cyclic citrullinated peptides.